VBL Therapeutics Investor Presentation — March 2021

Document content

Company Presentation

NASDAQ: VBLT March 2021

Totheextent that statements contained inthis presentation arenotdescriptions ofhistorical facts regarding Vascular Biogenics Ltd.,they areforward -

looking statements reflecting management ’scurrent beliefs and expectations .Forward -looking statements are subject toknown and unknown risks,

uncertainties, and other factors that may cause ourorourindustry ’sactual results, levels ofactivity, performance, orachievements tobematerially different

from those anticipated bysuch statements .You can identify forward -looking statements byterminology such as“may, ”“will,”“should, ”“expects, ”“plans, ”

“anticipates, ”“believes, ”“estimates, ”“predicts, ”“potential, ”“intends, ”or“continue, ”orthenegative ofthese terms orother comparable terminology .Forward -

looking statements contained inthis presentation include :(i)thetiming ofthecommencement, progress and receipt ofdata from pre-clinical studies and

clinical trials ;(ii)thetiming ofthecommencement, progress and receipt ofdata from anyother clinical trials that weconduct ;(iii)ourplans forfuture trials,

efficacy orclinical utility ofourproduct candidates ;(iv)ourplans forfuture trials ;(v)thescope ofprotection weestablish and maintain forintellectual

property rights covering ourproduct candidates and ourtechnology ;(vi)ourability toobtain and maintain regulatory approval forourproduct candidates and

thetiming orlikelihood ofregulatory filings and approvals forourproduct candidates ;and (vii) expectations relating tothecommercialization ofourproduct

Various factors may cause differences between ourexpectations and actual results, including unexpected safety orefficacy data, unexpected side effects

observed during preclinical studies orinclinical trials, lower than expected enrollment rates inclinical trials, changes inexpected orexisting competition,

changes intheregulatory environment forourdrug candidates andourneed forfuture capital, theinability toprotect ourintellectual property, andtheriskthat

webecome aparty tounexpected litigation orother disputes .You should read ourfilings with theSecurities and Exchange Commission, including theRisk

Factors setforth inourAnnual Report onForm 20-Ffortheyear ended December 31,2019 andourother filings with theSecurities andExchange Commission,

completely and with theunderstanding that ouractual future results may bematerially different from what weexpect .Except asrequired bylaw, weassume

noobligation toupdate these forward -looking statements publicly, ortoupdate thereasons why actual results could differ materially from those anticipated in

theforward -looking statements, even ifnew information becomes available inthefuture .